RCS - Arecor Therapeutics - TETRIS PHARMA LAUNCHES OGLUO® IN DENMARK & NORWAY

Arecor TherapeuticsAnnouncement

15/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230515:nRSO3362Za&default-theme=true

RNS Number : 3362Z  Arecor Therapeutics PLC  15 May 2023

Arecor Therapeutics plc

("Arecor", the "Company" or the "Group")

 

TETRIS PHARMA LAUNCHES OGLUO® IN DENMARK AND NORWAY

A new treatment option for severe hypoglycaemia for children and adults living
with diabetes

Launches build on continued roll out in Austria, Germany and the UK

 

Cambridge, UK, 15 May 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical company advancing today's therapies to enable healthier
lives, announces that subsidiary company, Tetris Pharma Ltd, has today
launched Ogluo® (glucagon prefilled autoinjector pen) in Denmark and Norway
as a treatment for severe hypoglycaemia in adults, adolescents, and children
aged two years and over living with diabetes mellitus.

See full Tetris Pharma announcement below:

15 May 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the Company"), a
subsidiary of biopharmaceutical company, Arecor Therapeutics plc (AIM: AREC),
today announces the launch of Ogluo® (glucagon prefilled autoinjector pen) in
Denmark and Norway as a treatment for severe hypoglycaemia in adults,
adolescents, and children aged two years and over living with diabetes
mellitus.

 

Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon in an
auto-injector for patients within the licenced indication living with diabetes
suffering from severe hypoglycaemia(1). Hypoglycaemia is a common and serious
complication of diabetes, particularly affecting people with diabetes on
insulin treatment. It is characterised by abnormally low blood sugar levels,
which can lead to cognitive impairment and in some severe cases, seizures,
loss of consciousness, coma and even death. It can have a profound effect on
the everyday lives of people with diabetes and their caregivers(2).

 

Ogluo® pricing has today been published in both Denmark and Norway allowing
patients to access this rescue medication, full prescribing information can be
found here (https://ogluo.info/) . Ogluo® is also available in Austria,
Germany and the UK. Tetris Pharma is working to commercialise Ogluo® in core
European markets as part of a pan-European commercialisation programme.

 

Dr Shafiq Choudhary, European Managing Director of Tetris Pharma said: "With
over half a million people estimated to be living with diabetes in Denmark and
Norway alone(3), the launch of Ogluo® gives patients living with diabetes an
alternative ready to use, ambient stored glucagon that can be kept by the
patients' side, giving their families and those around them the confidence to
manage severe hypoglycaemic events. The launch extends our commercial
footprint and pan-European presence."

 

1.      Ogluo SmPC

2.      Amiel, S.A. The consequences of hypoglycaemia. Diabetologia 64,
963-970 (2021). https://doi.org/10.1007/s00125-020-05366-3

3.      (IDF Atlas 10(th) Edition 2021 Diabetes report
https://diabetesatlas.org/data/en/country/148/no.html /
(https://diabetesatlas.org/data/en/country/148/no.html%20/)
https://www.diabetesatlas.org/data/en/country/56/dk.html
(https://www.diabetesatlas.org/data/en/country/56/dk.html) ) Access
Date:9/5/23

 

 

Enquiries:

 

Tetris Pharma

Dr Shafiq Choudhary      +44 (0)1628 337579

 

Notes to Editors

Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a commercial-stage
specialty pharmaceutical company with expertise in registering, marketing,
sales and the distribution of speciality hospital products across the UK and
Europe. Our experienced team has a proven history of building and growing
sales. Having secured distribution rights for already licensed products across
Europe, we have a portfolio of niche injectable products including Ogluo(®),
a ready-to-use glucagon for emergency use to treat hypoglycaemia. We
collaborate with partners to provide patients with effective treatments and
quality healthcare by ensuring we deliver accountability, partnership and
performance.

 

For further information, please visit tetrispharma.com
(http://tetrispharma.com)

 

-ENDS-

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications               Tel: +44 (0) 20 3709 5700

 Chris Gardner, David Daley, Lindsey Neville      Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAKSLFFEDEFA